L
Lorenzo G. Mantovani
Researcher at University of Milan
Publications - 361
Citations - 38356
Lorenzo G. Mantovani is an academic researcher from University of Milan. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 51, co-authored 324 publications receiving 26740 citations. Previous affiliations of Lorenzo G. Mantovani include University of Naples Federico II & University of Milano-Bicocca.
Papers
More filters
Journal ArticleDOI
Phm5 assessment of health-related quality of life in patients with haemophilia with the newly developed haemophilia-specific instrument haem-a-qol
TL;DR: Haem-A-QoL is a short and well-accepted questionnaire and shows quite satisfactory psychometric characteristics (reliability, validity) and is important to understand specific problems of haemophilic patients and to improve their treatment.
Journal ArticleDOI
Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up.
Domenico Ponticelli,Fabiana Madotto,Sara Conti,Ippazio Cosimo Antonazzo,Andrea Vitale,Giovanni Della Ragione,Maria L Romano,Mario Borrelli,Beniamino Schiavone,Riccardo Polosa,Pietro Ferrara,Lorenzo G. Mantovani +11 more
TL;DR: In this paper, the authors investigated the response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers (HCWs) in an Italian teaching hospital, where 444 participants were surveyed with either multiple RT-PCR assays for detection of SARS-CoV-2 nucleic acid in nasopharyngeal swabs or serology testing for the research of virus-specific immunoglobulins.
Journal ArticleDOI
Cardiac resynchronization therapy : a cost or an investment?
Giuseppe Boriani,Lorenzo G. Mantovani,Mauro Biffi,Martin J. Schalij,Cristian Martignani,Christophe Leclercq,Jeroen J. Bax,Angelo Auricchio +7 more
TL;DR: Clinical judgment in the context of current evidence supporting the benefits of cardioverter-defibrillators may provide a rational basis for choosing between CRT-P andCRT-D, which appears to meet the $50 000/QALY benchmark commonly used for health-care interventions in the USA, as well as similar thresholds used in Europe.
Journal ArticleDOI
Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group.
A. Nicholson,Karin Berger,Rhonda L. Bohn,Manuel Carcao,Krista Fischer,Alessandro Gringeri,K. Hoots,Lorenzo G. Mantovani,W. Schramm,BA Van Hout,Andrew R. Willan,B. M. Feldman +11 more
TL;DR: The IPSG has suggested minimal core standards to be applied to the reporting of economic evaluations of hemophilia prophylaxis to facilitate the comparison of studies and allow for more rational policy decisions and treatment choices.
Journal ArticleDOI
Subgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of Rivaroxaban versus Standard Anticoagulation for VTE.
Walter Ageno,Lorenzo G. Mantovani,Sylvia Haas,Reinhold Kreutz,Danja Monje,Jonas Schneider,Martin van Eickels,Martin Gebel,Alexander G.G. Turpie +8 more
TL;DR: In rivaroxaban-treated patients, rates for the primary outcomes were low, suggesting that patients administered rivroxaban were a good prognosis group, and the choice of anticoagulant varied with cancer type.